May 22nd 2025
This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body.
FDA Expands Access to Lumizyme, Drops Risk Mitigation Requirements
August 5th 2014With its expanded approval of Lumizyme (alglucosidase alfa) to treat all Pompe disease patients, regardless of age or time of disease onset, the FDA has eliminated the Risk Evaluation and Mitigation Strategy program that restricted the drug's use to those aged 8 years or older with late-onset disease.
Read More
Codeine Still Frequently Prescribed to Kids in Emergency Department
May 5th 2014The rate of prescription of codeine to children in emergency departments for injuries and cough and upper respiratory infection remained the same from 2001 through 2010 despite guidelines recommending against its use for these conditions.
Read More